Therapy Areas: Cardiovascular
Dermavant Sciences names new Directors
5 September 2018 -

Dermavant Sciences, a subsidiary of Roivant Pharma, announced yesterday that it has named Frank Torti, MD and Myrtle Potter as directors, with Dr Torti named Chairman of the Board.

Dr Torti serves as Vant Investment Chair for Roivant Pharma. He earlier served as a partner at New Enterprise Associates. Prior to joining New Enterprise Associates in 2007, Dr Torti was a researcher at the Duke University Center for Clinical & Genetic Economics.

Potter serves as Vant Operating Chair for Roivant Pharma. She earlier served as Chief Executive Officer of Myrtle Potter & Company and President and Chief Operating Officer of Genentech. Prior to Genentech she was president of Bristol-Myers Squibb's US Cardiovascular and Metabolic business.

Login
Username:

Password: